Select Page

COVID-19 update: April 29, 2022

COVID-19 update: April 29, 2022

COVID-19 Summary of Evidence report updated

The COVID-19 Summary of Evidence report has been updated with information to reflect that the Omicron subvariant BA.2 is prevalent and that long-term outcomes for recipients include the possibility of thrombotic events.

Compiled by the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC), the document includes the latest information known for minimizing the risk of donor-derived COVID-19 transmission while maximizing donor utilization.

The committee developed the summary in collaboration with colleagues representing AST, ASTS, AOPO, HRSA and the CDC. DTAC is reviewing the document on a quarterly basis.

FDA approves first COVID-19 treatment for young children

The U.S. Food and Drug Administration (FDA) has expanded the approval of Veklury (remdesivir) to include pediatric patients 28 days of age or older who weigh at least 3 kilograms and who are hospitalized or at high risk for progression to severe COVID-19.

FDA authorizes COVID-19 diagnostic test using breath samples

The new test detects chemicals compounds in breath samples associated with a SARS-CoV-2 infection.


Distribution of sotrovimab paused nationwide

  • The National Institute of Health’s (NIH) COVID-19 Treatment Guidelines Panel no longer recommends sotrovimab as a treatment option for non-hospitalized patients, citing substantially decreased in vitro activity against the dominant COVID-19 subvariant Omicron BA.2. Read the latest recommendations from NIH.

Help your patients locate Evusheld therapy

  • The U.S. Department of Health and Human Services maintains a national map displaying public locations that have received shipments of COVID-19 therapeutics such as Evusheld, Molnupiravir and Bebtelovimab. These therapies require a prescription, and the locator is intended for provider use.

The latest data on organ donation and transplant in the U.S.

  • Find high-level data on transplants, deceased donors recovered, patients added to the waitlist and patients temporarily moved to inactive waitlist status.


  • For COVID-19 related policy and operational questions, email [email protected]
  • For information and updates about the status of in-person vs. virtual OPTN committee meetings, check the OPTN calendar of events.

Patient-friendly information for members to share

Scan this QR code to find COVID-19 resources for patients at including:

QR code to

  • Frequently asked questions
  • Vaccine and treatment updates
  • Webinars
  • Spanish language resources

Download QR code

Share This